Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001917391-24-000008
Filing Date
2024-08-20
Accepted
2024-08-20 16:05:35
Documents
4
Period of Report
2024-08-12

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1724184329.html 3  
1 FORM 3 wk-form3_1724184329.xml 3 1709
2 EX-24 crbu-xsection16poa_alber.htm EX-24 4298
3 crbu-xsection16poa_alber001.jpg GRAPHIC 205477
4 crbu-xsection16poa_alber002.jpg GRAPHIC 35575
  Complete submission text file 0001917391-24-000008.txt   339655
Mailing Address 2929 7TH STREET, SUITE 105 BERKELEY CA 94710
Business Address 2929 7TH STREET, SUITE 105 BERKELEY CA 94710 510-982-6030
Caribou Biosciences, Inc. (Issuer) CIK: 0001619856 (see all company filings)

EIN.: 453728228 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O LYELL IMMUNOPHARMA, INC. 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address
Albertson Tina M. (Reporting) CIK: 0001917391 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40631 | Film No.: 241225108